Вот он почти новый золотой стандарт для женщин "за 30"
HPV Test More Accurate Than Pap Smear
From Tracee Cornforth,Your Guide to Women's Health.
Dateline: 09/14/99
A study published in the British Journal of Cancer this week shows that testing women over 35 for the human papillomavirus (HPV) is more accurate for detecting cervical diseases than the Pap smear. Overall, the HPV test accurately identified 20% more cervical disease than the Pap smear.
The possible HPV-cervical cancer connection has been understood for sometime. However, other recent news from Britain reveals that HPV is the cause of 99.7% of all cases of cervical cancer.
The British Journal of Cancer study demonstrated the effectiveness of HPV testing in the early diagnosis of cervical disease in women over 35--the group most at risk for developing cervical cancer. The findings of this study suggest that incorporating HPV testing in cervical cancer screening could significantly reduce the number of deaths from cervical cancer.
Almost three thousand British women, participated in the study which drew women from 40 general medical practices within the UK's Hammersmith Health Authority. The women received HPV testing as well as Pap smears during their routine physicals.
After examining the results, researchers concluded that HPV testing, using the Digene Hybrid Capture II HPV Test, had a sensitivity to detect moderate or high-grade cervical disease in 95% of cases, as compared to the sensitivity of the Pap smear, which detected 79%.
According to a Digene press release, Professor Jack Cuzick who led the research said, "Virtually all cases of cervical cancer are positive for HPV. By testing for the presence of this virus, the detection of cervical disease is improved and there is the potential to save even more lives than with the current screening program in the United Kingdom. It might also be possible to safely extend the screening interval for women who are HPV negative, thus reducing the costs of cervical screening.
The Digene Hybrid Capture II HPV Test is the only test for HPV approved by the FDA in the United States as an adjunct to the Pap smear for cervical cancer screening.
Approximately 50 million Pap smears are performed annually in the United States with 3.5 million women diagnosed with ASCUS (atypical cells of undetermined significance) or borderline Pap smear results. Fifteen thousand women in the United States are diagnosed with cervical cancer each year and 5000 of these women die of the cancer. Worldwide cervical cancer affects 500,000 women annually.